473 related articles for article (PubMed ID: 23957828)
1. The TWEAK-Fn14 system as a potential drug target.
Wajant H
Br J Pharmacol; 2013 Oct; 170(4):748-64. PubMed ID: 23957828
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity.
Salzmann S; Seher A; Trebing J; Weisenberger D; Rosenthal A; Siegmund D; Wajant H
J Biol Chem; 2013 May; 288(19):13455-66. PubMed ID: 23532848
[TBL] [Abstract][Full Text] [Related]
3. TWEAK/Fn14 interaction regulates RANTES production, BMP-2-induced differentiation, and RANKL expression in mouse osteoblastic MC3T3-E1 cells.
Ando T; Ichikawa J; Wako M; Hatsushika K; Watanabe Y; Sakuma M; Tasaka K; Ogawa H; Hamada Y; Yagita H; Nakao A
Arthritis Res Ther; 2006; 8(5):R146. PubMed ID: 16945157
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor-like weak inducer of apoptosis and fibroblast growth factor-inducible 14 mediate cerebral ischemia-induced poly(ADP-ribose) polymerase-1 activation and neuronal death.
Haile WB; Echeverry R; Wu F; Guzman J; An J; Wu J; Yepes M
Neuroscience; 2010 Dec; 171(4):1256-64. PubMed ID: 20955770
[TBL] [Abstract][Full Text] [Related]
5. Studies of binding of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) to fibroblast growth factor inducible 14 (Fn14).
Fick A; Lang I; Schäfer V; Seher A; Trebing J; Weisenberger D; Wajant H
J Biol Chem; 2012 Jan; 287(1):484-495. PubMed ID: 22081603
[TBL] [Abstract][Full Text] [Related]
6. Interaction of TWEAK with Fn14 leads to the progression of fibrotic liver disease by directly modulating hepatic stellate cell proliferation.
Wilhelm A; Shepherd EL; Amatucci A; Munir M; Reynolds G; Humphreys E; Resheq Y; Adams DH; Hübscher S; Burkly LC; Weston CJ; Afford SC
J Pathol; 2016 May; 239(1):109-21. PubMed ID: 26924336
[TBL] [Abstract][Full Text] [Related]
7. TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade.
van Kuijk AW; Wijbrandts CA; Vinkenoog M; Zheng TS; Reedquist KA; Tak PP
Ann Rheum Dis; 2010 Jan; 69(1):301-4. PubMed ID: 19147618
[TBL] [Abstract][Full Text] [Related]
8. The cytokine tumor necrosis factor-like weak inducer of apoptosis and its receptor fibroblast growth factor-inducible 14 have a neuroprotective effect in the central nervous system.
Echeverry R; Wu F; Haile WB; Wu J; Yepes M
J Neuroinflammation; 2012 Mar; 9():45. PubMed ID: 22394384
[TBL] [Abstract][Full Text] [Related]
9. TWEAK/Fn14 promotes pro-inflammatory cytokine secretion in hepatic stellate cells via NF-κB/STAT3 pathways.
Wang A; Zhang F; Xu H; Xu M; Cao Y; Wang C; Xu Y; Su M; Zhang M; Zhuge Y
Mol Immunol; 2017 Jul; 87():67-75. PubMed ID: 28411440
[TBL] [Abstract][Full Text] [Related]
10. Structural basis and targeting of the interaction between fibroblast growth factor-inducible 14 and tumor necrosis factor-like weak inducer of apoptosis.
Dhruv H; Loftus JC; Narang P; Petit JL; Fameree M; Burton J; Tchegho G; Chow D; Yin H; Al-Abed Y; Berens ME; Tran NL; Meurice N
J Biol Chem; 2013 Nov; 288(45):32261-32276. PubMed ID: 24056367
[TBL] [Abstract][Full Text] [Related]
11. Functional expression of TWEAK and the receptor Fn14 in human malignant ovarian tumors: possible implication for ovarian tumor intervention.
Gu L; Dai L; Cao C; Zhu J; Ding C; Xu HB; Qiu L; Di W
PLoS One; 2013; 8(3):e57436. PubMed ID: 23469193
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory cytokines and survival factors from serum modulate tweak-induced apoptosis in PC-3 prostate cancer cells.
Sanz AB; Sanchez-Niño MD; Carrasco S; Manzarbeitia F; Ruiz-Andres O; Selgas R; Ruiz-Ortega M; Gonzalez-Enguita C; Egido J; Ortiz A
PLoS One; 2012; 7(10):e47440. PubMed ID: 23077618
[TBL] [Abstract][Full Text] [Related]
13. The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression.
Tran NL; McDonough WS; Savitch BA; Sawyer TF; Winkles JA; Berens ME
J Biol Chem; 2005 Feb; 280(5):3483-92. PubMed ID: 15611130
[TBL] [Abstract][Full Text] [Related]
14. Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells.
Roos A; Dhruv HD; Mathews IT; Inge LJ; Tuncali S; Hartman LK; Chow D; Millard N; Yin HH; Kloss J; Loftus JC; Winkles JA; Berens ME; Tran NL
Oncotarget; 2017 Feb; 8(7):12234-12246. PubMed ID: 28103571
[TBL] [Abstract][Full Text] [Related]
15. TWEAK-independent Fn14 self-association and NF-κB activation is mediated by the C-terminal region of the Fn14 cytoplasmic domain.
Brown SA; Cheng E; Williams MS; Winkles JA
PLoS One; 2013; 8(6):e65248. PubMed ID: 23750247
[TBL] [Abstract][Full Text] [Related]
16. Role of the TWEAK/Fn14 pathway in autoimmune diseases.
Xu WD; Zhao Y; Liu Y
Immunol Res; 2016 Feb; 64(1):44-50. PubMed ID: 26659091
[TBL] [Abstract][Full Text] [Related]
17. TWEAK/Fn14 signaling is required for liver regeneration after partial hepatectomy in mice.
Karaca G; Swiderska-Syn M; Xie G; Syn WK; Krüger L; Machado MV; Garman K; Choi SS; Michelotti GA; Burkly LC; Ochoa B; Diehl AM
PLoS One; 2014; 9(1):e83987. PubMed ID: 24416188
[TBL] [Abstract][Full Text] [Related]
18. TWEAK as a target for therapy in systemic lupus erythematosus.
Leng RX; Pan HF; Qin WZ; Wang C; Chen LL; Tao JH; Ye DQ
Mol Biol Rep; 2011 Jan; 38(1):587-92. PubMed ID: 20358293
[TBL] [Abstract][Full Text] [Related]
19. Roles of tumour necrosis factor-related weak inducer of apoptosis/fibroblast growth factor-inducible 14 pathway in lupus nephritis.
Chen J; Wei L; Xia Y
Nephrology (Carlton); 2017 Feb; 22(2):101-106. PubMed ID: 27786399
[TBL] [Abstract][Full Text] [Related]
20. The interaction between tumor necrosis factor-like weak inducer of apoptosis and its receptor fibroblast growth factor-inducible 14 promotes the recruitment of neutrophils into the ischemic brain.
Haile WB; Echeverry R; Wu J; Yepes M
J Cereb Blood Flow Metab; 2010 Jun; 30(6):1147-56. PubMed ID: 20068578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
